NASDAQ:TECX Tectonic Therapeutic (TECX) Stock Price, News & Analysis $27.21 -0.70 (-2.51%) Closing price 04:00 PM EasternExtended Trading$27.18 -0.03 (-0.09%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Tectonic Therapeutic Stock (NASDAQ:TECX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tectonic Therapeutic alerts:Sign Up Key Stats Today's Range$27.11▼$28.7150-Day Range$27.91▼$37.7152-Week Range$14.39▼$39.53Volume186,771 shsAverage Volume262,419 shsMarket Capitalization$531.96 millionP/E RatioN/ADividend YieldN/APrice Target$77.25Consensus RatingModerate Buy Company Overview Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on developing biologic medicines that target G protein-coupled receptors (GPCRs). These receptors play important roles in many physiological processes but have historically been difficult to address with conventional antibody-based therapies. The company uses its proprietary GEODe platform to discover and develop antibodies and other biologics designed to modulate GPCR activity. Tectonic’s pipeline includes TX45, an investigational therapeutic intended to activate the relaxin receptor RXFP1. The company is evaluating this program for potential use in cardiovascular diseases, including heart failure with preserved ejection fraction and other conditions associated with impaired vascular function. Tectonic Therapeutic was founded in 2019 and is headquartered in the United States. Its research and development activities are focused on advancing GPCR-directed biologics through clinical development, with the goal of addressing significant unmet medical needs in cardiovascular and other disease areas.AI Generated. May Contain Errors. Read More Tectonic Therapeutic Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreTECX MarketRank™: Tectonic Therapeutic scored higher than 54% of companies evaluated by MarketBeat, and ranked 408th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingTectonic Therapeutic has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTectonic Therapeutic has a consensus price target of $77.25, representing about 183.9% upside from its current price of $27.21.Amount of Analyst CoverageTectonic Therapeutic has only been the subject of 4 research reports in the past 90 days.Read more about Tectonic Therapeutic's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tectonic Therapeutic are expected to decrease in the coming year, from ($5.25) to ($5.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tectonic Therapeutic is -5.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tectonic Therapeutic is -5.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTectonic Therapeutic has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tectonic Therapeutic's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.51% of the float of Tectonic Therapeutic has been sold short.Short Interest Ratio / Days to CoverTectonic Therapeutic has a short interest ratio ("days to cover") of 7.59.Change versus previous monthShort interest in Tectonic Therapeutic has recently increased by 12.48%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTectonic Therapeutic does not currently pay a dividend.Dividend GrowthTectonic Therapeutic does not have a long track record of dividend growth. News and Social Media2.7 / 5News SentimentN/A News SentimentTectonic Therapeutic has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Tectonic Therapeutic this week, compared to 1 article on an average week. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tectonic Therapeutic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,095.00 in company stock.Percentage Held by Insiders39.80% of the stock of Tectonic Therapeutic is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.63% of the stock of Tectonic Therapeutic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tectonic Therapeutic's insider trading history. Receive TECX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tectonic Therapeutic and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TECX Stock News HeadlinesTectonic Therapeutic, Inc. (NASDAQ:TECX) Receives $77.80 Consensus Target Price from AnalystsSeptember 6, 2026 | americanbankingnews.comTectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare ConferenceSeptember 3, 2026 | globenewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 17 at 1:00 AM | Porter & Company (Ad)Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull CaseSeptember 2, 2026 | seekingalpha.comStifel Nicolaus Reaffirms Their Buy Rating on Tectonic Therapeutic (TECX)August 13, 2026 | theglobeandmail.comAnalysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), InflaRx (IFRX) and Tectonic Therapeutic (TECX)August 7, 2026 | theglobeandmail.comTectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business HighlightsAugust 6, 2026 | finance.yahoo.comTectonic Therapeutic IncJuly 2, 2026 | edition.cnn.comSee More Headlines TECX Stock Analysis - Frequently Asked Questions How have TECX shares performed this year? Tectonic Therapeutic's stock was trading at $20.86 on January 1st, 2026. Since then, TECX stock has increased by 30.4% and is now trading at $27.21. How were Tectonic Therapeutic's earnings last quarter? Tectonic Therapeutic, Inc. (NASDAQ:TECX) announced its earnings results on Thursday, August, 6th. The company reported ($1.18) EPS for the quarter, beating analysts' consensus estimates of ($1.35) by $0.17. When did Tectonic Therapeutic IPO? Tectonic Therapeutic (TECX) raised $89 million in an IPO on Thursday, June 21st 2018. The company issued 5,247,958 shares at $16.00-$18.00 per share. Who are Tectonic Therapeutic's major shareholders? Top institutional investors of Tectonic Therapeutic include BlackRock Inc. (4.57%), First Light Asset Management LLC (4.10%), 5AM Venture Management LLC (3.10%) and Braidwell LP (3.05%). Insiders that own company stock include Timothy A Springer, Marcella K Ruddy, Peter Mcnamara and Daniel Lochner. View institutional ownership trends. How do I buy shares of Tectonic Therapeutic? Shares of TECX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tectonic Therapeutic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tectonic Therapeutic investors own include Waste Connections (WCN), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/06/2026Today9/17/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 TECX's financial health is in the Green zone, according to TradeSmith. TECX has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TECX Previous SymbolNASDAQ:TECX CIK1681087 Webwww.tectonictx.com Phone617-914-8420FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for Tectonic Therapeutic$77.25 High Price Target$93.00 Low Price Target$60.00 Potential Upside/Downside+183.9%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($4.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.15 million Net MarginsN/A Pretax MarginN/A Return on Equity-35.26% Return on Assets-33.59% Debt Debt-to-Equity RatioN/A Current Ratio22.29 Quick Ratio22.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.43 per share Price / Book2.03Miscellaneous Outstanding Shares19,550,000Free Float11,768,000Market Cap$531.96 million OptionableN/A Beta3.31 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:TECX) was last updated on 9/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tectonic Therapeutic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tectonic Therapeutic With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TECX Stock Alerts